AMAL Therapeutics to publish research outcomes in Cancers

Geneva, Switzerland, December 3, 2021 – AMAL Therapeutics announced today that the latest findings of its research team is on line on the Cancers website. Results show that the heterologous prime-boost combination with a protein vaccine and a viral vector vesicular stomatitis virus immunologically reshapes TC-1 cold tumor model by recruiting cross-presenting dendritic cells, and polarizing CD4+ T cells towards an antitumor Th1 phenotype within the tumor and tumor-draining lymph nodes. Additionally, this study also highlights the design of a multi-epitope vaccine for cancer immunotherapy as shown in the MC-38 inflamed tumor model.

PDF icon Full article in .pdf

Share this entry

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: